Video
Dr. Min Dong discusses ongoing research with onabotulinumtoxinA for patients with urologic disease
Author(s):
“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.
Video Player is loading.
In this video, Min Dong, MD, summarizes the ongoing and future research related to Botox therapies for urologic diseases. These ideas stem from the talk he gave at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting, titled, “New frontiers in therapeutic toxins for urologic disease.” Dong is an associate professor of urology at Harvard Medical School in Cambridge, Massachusetts.
Related Videos
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Related Content
